To explore whether targeting CAIX activity in the context of anti-angiogenic agents may improve efficacy in the setting of TNBC in vivo, we focused our studies on the highly metastatic, CAIX-positive, MDA-MB-231 LM2-4Luc+ orthotopic human breast tumor model [5]. Here, CA9 is linked to breast neoplasm.